Clara Mukuria1, Donna Rowen2, John E Brazier2, Tracey A Young2, Beenish Nafees3. 1. Health Economics and Decision Science, School of Health and Related Research, The University of Sheffield, Sheffield, UK. Electronic address: c.mukuria@sheffield.ac.uk. 2. Health Economics and Decision Science, School of Health and Related Research, The University of Sheffield, Sheffield, UK. 3. ICON plc, Dublin, Ireland.
Abstract
BACKGROUND: Utility values are required for economic evaluation using cost-utility analyses. Often, generic measures such as the EuroQol five-dimensional questionnaire are used, but this may not appropriately reflect the health-related quality of life of patients with cancer including myelofibrosis. OBJECTIVE: To derive a condition-specific preference-based measure for myelofibrosis using appropriate existing measures, the Myelofibrosis-Symptom Assessment Form and the European Organisation for Research and Treatment of Cancer Quality of Life 30 Questionnaire. METHODS: Data from the Controlled Myelofibrosis Study with Oral JAK Inhibitor Treatment trial (n = 309) were used to derive the health state classification system. Psychometric and factor analyses were used to determine the dimensions of the classification system. Psychometric and Rasch analyses were then used to select an item to represent each dimension. Item selection was validated with experts. A selection of health states was valued by members of the general population using time trade-off. Finally, health state values were modeled using regression analysis to produce utility values for every state. RESULTS: The Myelofibrosis 8 dimensions has eight dimensions: physical functioning, emotional functioning, fatigue, itchiness, pain under ribs on the left side, abdominal discomfort, bone or muscle pain, and night sweats. Regression models were estimated using time trade-off data from 246 members of the general population valuing a total of 33 states. The best performing model was a random effects maximum likelihood model producing utility values ranging from 0.089 to 1. CONCLUSIONS: The Myelofibrosis 8 dimensions is a condition-specific preference-based measure for myelofibrosis. This measure can be used to generate utility values for myelofibrosis for any data set containing the Myelofibrosis-Symptom Assessment Form and the European Organisation for Research and Treatment of Cancer Quality of Life 30 Questionnaire data.
BACKGROUND: Utility values are required for economic evaluation using cost-utility analyses. Often, generic measures such as the EuroQol five-dimensional questionnaire are used, but this may not appropriately reflect the health-related quality of life of patients with cancer including myelofibrosis. OBJECTIVE: To derive a condition-specific preference-based measure for myelofibrosis using appropriate existing measures, the Myelofibrosis-Symptom Assessment Form and the European Organisation for Research and Treatment of Cancer Quality of Life 30 Questionnaire. METHODS: Data from the Controlled Myelofibrosis Study with Oral JAK Inhibitor Treatment trial (n = 309) were used to derive the health state classification system. Psychometric and factor analyses were used to determine the dimensions of the classification system. Psychometric and Rasch analyses were then used to select an item to represent each dimension. Item selection was validated with experts. A selection of health states was valued by members of the general population using time trade-off. Finally, health state values were modeled using regression analysis to produce utility values for every state. RESULTS: The Myelofibrosis 8 dimensions has eight dimensions: physical functioning, emotional functioning, fatigue, itchiness, pain under ribs on the left side, abdominal discomfort, bone or muscle pain, and night sweats. Regression models were estimated using time trade-off data from 246 members of the general population valuing a total of 33 states. The best performing model was a random effects maximum likelihood model producing utility values ranging from 0.089 to 1. CONCLUSIONS: The Myelofibrosis 8 dimensions is a condition-specific preference-based measure for myelofibrosis. This measure can be used to generate utility values for myelofibrosis for any data set containing the Myelofibrosis-Symptom Assessment Form and the European Organisation for Research and Treatment of Cancer Quality of Life 30 Questionnaire data.
Authors: Fanni Rencz; Petra Baji; László Gulácsi; Sarolta Kárpáti; Márta Péntek; Adrienn Katalin Poór; Valentin Brodszky Journal: Qual Life Res Date: 2015-12-18 Impact factor: 4.147
Authors: Sanjeewa Kularatna; Donna Rowen; Clara Mukuria; Steven McPhail; Gang Chen; Brendan Mulhern; Jennifer A Whitty; Joshua Byrnes; Paul Scuffham; John Atherton; Stefan Höfer; William Parsonage Journal: Qual Life Res Date: 2021-05-26 Impact factor: 4.147
Authors: Madeleine T King; Rosalie Viney; A Simon Pickard; Donna Rowen; Neil K Aaronson; John E Brazier; David Cella; Daniel S J Costa; Peter M Fayers; Georg Kemmler; Helen McTaggart-Cowen; Rebecca Mercieca-Bebber; Stuart Peacock; Deborah J Street; Tracey A Young; Richard Norman Journal: Pharmacoeconomics Date: 2018-02 Impact factor: 4.981